Family Newsletter from the Comprehensive Hemostasis and Thrombosis Center at Children’s Hospital of Philadelphia.

Researchers at Children’s Hospital of Philadelphia (CHOP) found that emicizumab, a widely used drug for hemophilia A, could also improve blood clotting for select people with hemophilia B depending on their genes. The preclinical study, recently published in Blood, offers proof that this class of hemophilia A drug could potentially be used to treat hemophilia B.

The findings show how more rapid results can improve practice and lead to more accurate and timely diagnoses

Alexis A. Thompson, MD, MPH, chief, Division of Hematology, and the Elias Schwartz MD Endowed Chair in Hematology at CHOP, has been recognized for her leadership in sickle cell disease (SCD) treatment and research.

CHOP announced that its first patients outside of clinical trials have begun the treatment process for the newly FDA approved sickle cell gene therapies.

Researchers at CHOP announced the results of a new study offering insights into the development of next-generation gene therapies to treat hemophilia A.

Researchers at Children’s Hospital of Philadelphia (CHOP) announced a significant breakthrough in understanding chemotherapy resistance in high-risk neuroblastoma, a common and potentially deadly childhood cancer arising within the peripheral nervous system.

The life and legacy of the late Dr. Kwaku Ohene-Frempong was celebrated by family, friends and colleagues at his portrait unveiling ceremony on CHOP’s campus on June 20.

Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine pioneered a new model that offers a potential platform for developing novel therapies to treat Alpha Thalassemia (AT), a severe blood disorder. The findings were published in the journal Blood.

Earlier this month, Children’s Hospital of Philadelphia (CHOP) hosted the Cure Sickle Cell Walk & Family Fun Day presented by West Pharmaceutical Services at Citizens Bank Park raising more than $256,000 (and counting!) to support sickle cell warriors.